51207-86-4

Basic information

• Product Name: (4-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE
• Synonyms: CHEMBRDG-BB 3000462;BUTTPARK 19\02-43;ART-CHEM-BB B000462;(4-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE;(4-AMINOPHENYL)(MORPHOLINO)METHANONE;4-AMINOBENZOIC ACID, MORPHOLIDE;4-(MORPHOLIN-4-YLCARBONYL)PHENYLAMINE;AKOS B000462
• CAS NO: 51207-86-4
• Molecular Formula: C₁₁H₁₄N₂O₂
• Molecular Weight: 206.24
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 51207-86-4.mol
• Article Data: 40

Chemical Properties

• Melting Point: 132-135°C
• Boiling Point: 426.9°C at 760 mmHg
• Flash Point: 212°C
• Appearance: /
• Density: 1.228g/cm³
• Vapor Pressure: 1.71E-07mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.43±0.10(Predicted)
• CAS DataBase Reference: (4-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE(51207-86-4)
• EPA Substance Registry System: (4-AMINO-PHENYL)-MORPHOLIN-4-YL-METHANONE(51207-86-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 51207-86-4(Hazardous Substances Data)

Usage

Uses

(4-Amino-Phenyl)-Morpholin-4-yl-Methanone is an morpholine derivative used in the preparation of tyrosine kinase inhibitors and other biologically active agents.

InChI:InChI=1/C11H14N2O2/c12-10-3-1-9(2-4-10)11(14)13-5-7-15-8-6-13/h1-4H,5-8,12H2

Upstream product

• 15159-40-7 4-morpholinocarbonyl chloride 
• 540-37-4 p-aminoiodobenzene 
• 110-91-8 morpholine 
• 636-98-6 p-nitrobenzene iodide 
• 201230-82-2 carbon monoxide 
• 619-45-4 4-methoxycarbonyl aniline 
• 556-18-3 4-aminobenzaldehyde 
• 106-40-1 4-bromo-aniline 
• 62-23-7 4-nitro-benzoic acid 
• 150-13-0 4-amino-benzoic acid 
• 1090724-68-7 tert-butyl (4-(morpholine-4-carbonyl)phenyl)carbamate 
• 122-04-3 4-nitro-benzoyl chloride 
• 5397-76-2 1-morpholin-4-yl-1-(4-nitro-phenyl)-methanone 

Downstream Products

• 72767-23-8 4-[4-(benzo[1,2,3]triazol-1-ylmethyl-amino)-benzoyl]-morpholine 
• 72752-78-4 4-{4-[(4-oxo-4H-quinazolin-3-ylmethyl)-amino]-benzoyl}-morpholine 
• 72752-59-1 4-{4-[(2-oxo-benzooxazol-3-ylmethyl)-amino]-benzoyl}-morpholine 
• 72752-64-8 4-{4-[(2-thioxo-benzooxazol-3-ylmethyl)-amino]-benzoyl}-morpholine 
• 56415-53-3 4-[4-(2,5-dioxo-3-pentyl-pyrrolidin-1-yl)-benzoyl]-morpholine 
• 72752-74-0 4-[4-(phthalimidomethyl-amino)-benzoyl]-morpholine 
• 72752-76-2 4-{4-[(5-nitro-1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-amino]-benzoyl}-morpholine 
• 104183-62-2 5-(p-Fluorobenzylidene)-3--4-oxo-thiazolidine-2-thione 
• 104183-51-9 5-(p-Methoxybenzylidene)-3--4-oxo-thiazolidine-2-thione 
• 104183-55-3 5-(p-Dimethylaminobenzylidene)-3--4-oxo-thiazolidine-2-thione 
• 81820-29-3 3-[4-(Morpholine-4-carbonyl)-phenyl]-2-phenyl-5-[1-phenyl-meth-(Z)-ylidene]-3,5-dihydro-imidazol-4-one 
• 81820-34-0 5-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-3-[4-(morpholine-4-carbonyl)-phenyl]-2-phenyl-3,5-dihydro-imidazol-4-one 
• 81820-38-4 5-[1-(2-Methoxy-phenyl)-meth-(Z)-ylidene]-3-[4-(morpholine-4-carbonyl)-phenyl]-2-phenyl-3,5-dihydro-imidazol-4-one 
• 1206706-48-0 (4-(6-amino-3-(2-methyl-3-nitrophenyl)-1,2,4-triazin-5-ylamino)phenyl)(morpholino)methanone 

Relevant articles and documents

Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors

The cysteine proteases, cruzain and TbrCATL (rhodesain), are therapeutic targets for Chagas disease and Human African Trypanosomiasis, respectively. Among the known inhibitors for these proteases, we have described N4-benzyl-N2-phenylquinazoline-2,4-diamine (compound 7 in the original publication, 1a in this study), as a competitive cruzain inhibitor (Ki = 1.4 μM). Here, we describe the synthesis and biological evaluation of 22 analogs of 1a, containing modifications in the quinazoline core, and in the substituents in positions 2 and 4 of this ring. The analogs demonstrate low micromolar inhibition of the target proteases and cidal activity against Trypanosoma cruzi with up to two log selectivity indices in counterscreens with myoblasts. Fourteen compounds were active against Trypanosoma brucei at low to mid micromolar concentrations. During the optimization of 1a, structure-based design and prediction of physicochemical properties were employed to maintain potency against the enzymes while removing colloidal aggregator characteristics observed for some molecules in this series.

Double carbonylation of iodoarenes in the presence of a pyridinium SILP-Pd catalyst

The efficiency of a palladium catalyst, immobilised on a supported ionic liquid phase (SILP) with adsorbed 1-butyl-4-methylpyridinium chloride, was investigated in aminocarbonylation reactions. Double carbonylation was found to be the main reaction using different iodoarenes and aliphatic amines as substrates. Application of aniline derivatives as nucleophiles led to the exclusive formation of substituted benzamides. The stabilisation effect of the adsorbed pyridinium ionic liquid was compared to that of imidazolium and phosphonium derivatives. It was proved that the pyridinium SILP-palladium catalyst could be reused in at least 10 cycles. Recyclability was tested in five successive runs for all of the substrates.

S-triazine compounds as well as preparation method and application thereof

The invention discloses s-triazine compounds and pharmaceutically acceptable salts thereof; experiments prove that the compounds can be used for treating or preventing diseases related to protein kinase activity, such as leukemia and lymphoma, by inhibiti